BPC-157 therapy resolves liver fibrosis, portal hypertension, and inflammation in rats with bile duct ligation
Background
Chronic liver disease, often progressing to fibrosis and cirrhosis, is a major health challenge. One experimental model to study this is bile duct ligation (BDL), which simulates obstructive cholestasis, leading to liver damage, fibrosis, portal hypertension, and systemic inflammation. Key mediators in this damage include oxidative stress (measured by malondialdehyde (MDA)) and nitric oxide dysregulation (via NOS2 and NOS3 pathways). Current treatments for advanced liver fibrosis are limited, creating a need for novel therapeutic agents that can counteract the complex pathology involving cell death (apoptosis, necrosis), inflammation (driven by cytokines like TNF-α and IL-6), and structural changes (collagen deposition, stellate cell activation). The stable gastric pentadecapeptide BPC-157 is being investigated for its cytoprotective and healing properties across various tissues, making it a candidate for mitigating such severe liver injury.
Study Design
This study used rats with surgically induced bile duct ligation (BDL) to model liver fibrosis and portal hypertension. BPC-157 therapy was administered through several regimens. One group received BPC-157 (10 μg/kg or 10 ng/kg) continuously in their drinking water starting immediately after surgery. Another group started this oral therapy at week 4 post-surgery. A separate group received intraperitoneal injections of BPC-157, with the first dose 30 minutes post-ligation and the last dose 24 hours before sacrifice. A final intervention involved a local bath of BPC-157 (10 µg/kg) directly applied to assess immediate effects on portal hypertension at weeks 4, 6, and 8. Control rats underwent BDL without receiving BPC-157. Researchers assessed outcomes via histology (Ki-67, α-SMA, Mallory staining), serum biomarkers (AST, ALT, bilirubin), and tissue analysis (Western blot for NOS2/NOS3, cytokine levels).
Results
BPC-157 therapy significantly counteracted the severe pathology in BDL-rats. The treatment markedly reduced physical symptoms like jaundice, ascites, and nodular, steatotic livers. Histological analysis showed BPC-157 counteracted piecemeal necrosis, apoptosis, inflammation, and abnormal collagen deposition. It also normalized cytoskeletal structure in hepatic stellate cells, a key driver of fibrosis. BPC-157 administration reversed elevated serum levels of liver enzymes (AST, ALT, GGT, ALP) and total, direct, and indirect bilirubin, while also correcting decreased albumin levels. Critically, the therapy normalized tissue levels of oxidative stress marker MDA and nitric oxide, supported by Western blot analysis of NOS2 and NOS3 expression. It also decreased pro-inflammatory cytokines IL-6, TNF-α, and IL-1β in liver tissue.
The study found that depending on the administration regimen, BPC-157 either prevented the development of portal hypertension entirely or rapidly abated it once established.
Key Findings
- BPC-157 given at 10 μg/kg or 10 ng/kg reversed elevated MDA and NO tissue values back to healthy levels in BDL-rats.
- Therapy abated jaundice, ascites, and steatotic liver changes observed in control animals from the 4th week onwards.
- BPC-157 counteracted increases in serum AST, ALT, GGT, ALP, and total bilirubin, while normalizing decreased albumin.
- The peptide decreased levels of inflammatory cytokines IL-6, TNF-α, and IL-1β in liver tissue.
- Depending on the regimen, BPC-157 either prevented the development of portal hypertension or rapidly reversed it upon administration.
Why It Matters
The findings suggest that BPC-157 has potent hepatoprotective and anti-fibrotic properties, capable of reversing multiple facets of severe liver damage from cholestasis. For researchers and biohackers exploring BPC-157, this study highlights its potential beyond musculoskeletal repair, extending to complex internal organ pathologies like liver fibrosis. The efficacy of both oral (drinking water) and injectable routes provides flexibility. This suggests BPC-157 could be a viable agent to combat liver fibrosis and its severe complication, portal hypertension. Clinically, this is a preclinical animal study, and human trials are needed to establish safety, dosing, and efficacy. However, given the lack of effective treatments for advanced fibrosis, these results provide a strong rationale for further investigation. The data supports both prophylactic use (preventing hypertension) and therapeutic use (reversing existing hypertension), which could influence future protocol design.
TitrateLab articles covering BPC-157
Written by TitrateLab, separately from the study summarized above.
